Therapeutic advances: new hope for patients with ALS.
Forshew
D A
DA
Department of Neurology, University of Utah, Salt Lake City, USA.
D000085:Acetates / Q000627:therapeutic use; D000368:Aged; D000588:Amines; D000690:Amyotrophic Lateral Sclerosis / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D003509:Cyclohexanecarboxylic Acids; D018755:GABA Agonists / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D008134:Long-Term Care; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010353:Patient Education as Topic; D019782:Riluzole / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D018755:GABA Agonists; D018696:Neuroprotective Agents; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D019782:Riluzole